Neurofibromatosis Type 1

Detailed Overview

NF1 is one of the most common neurogenetic disorders. The NF1 gene encodes neurofibromin, a tumor suppressor protein that negatively regulates the RAS signaling pathway. Loss of neurofibromin leads to uncontrolled cell proliferation. Clinical features typically appear in early childhood, starting with café-au-lait macules and axillary freckling, followed by Lisch nodules in the eyes and neurofibromas. While most tumors are benign, patients have a high risk of developing malignant peripheral nerve sheath tumors (MPNST), optic pathway gliomas, and other cancers. Management requires multidisciplinary lifelong surveillance.

Epidemiology & Demographics

Incidence is roughly 1 in 3,000 live births worldwide. It affects all ethnicities and both sexes equally. About 50% of cases are familial, and 50% represent de novo mutations.

Etiological Mechanism

Caused by heterozygous loss-of-function mutations in the NF1 gene located on chromosome 17q11.2.

Primary Causes

Inherited mutation of the NF1 gene (autosomal dominant)

Spontaneous de novo mutation of the NF1 gene

• Family History: Having a parent with NF1 gives a 50% chance of inheriting the disorder.

The NF1 gene encodes neurofibromin, a GTPase-activating protein (GAP) that normally inactivates RAS by converting active RAS-GTP to inactive RAS-GDP. Mutation results in non-functional neurofibromin, leading to constitutively active RAS signaling. This drives the MAPK and PI3K/mTOR pathways, promoting rampant cellular proliferation and tumorigenesis, particularly in Schwann cells, melanocytes, and bone cells. A 'second hit' (somatic mutation of the remaining normal allele) in Schwann cells is required for the formation of neurofibromas.

Characteristic Clinical Presentation

• Skin spots: Flat, light-brown patches on the skin (Café-au-lait spots).
• Bumps under the skin: Soft, painless lumps (cutaneous neurofibromas) that increase in number during puberty.
• Vision problems: Decreased visual acuity or proptosis if an optic pathway glioma is present.
• Learning disabilities: Cognitive impairment, ADHD, and specific learning disabilities are seen in 50-70% of patients.

Physical Examination Signs

• Café-au-lait macules: ≥6 spots, >5 mm in prepubertal or >15 mm in postpubertal individuals.
• Freckling in axillary or inguinal regions (Crowe sign).
• Lisch nodules: ≥2 pigmented iris hamartomas seen on slit-lamp exam.
• Plexiform neurofibromas: Large, infiltrative nerve sheath tumors feeling like a 'bag of worms'.
• Sphenoid dysplasia or tibial pseudarthrosis.

• Malignant Peripheral Nerve Sheath Tumor (MPNST): Aggressive sarcoma arising from pre-existing plexiform neurofibromas in 8-13% of patients.
• Optic Pathway Glioma: Low-grade pilocytic astrocytoma affecting the optic nerve/chiasm; can cause blindness.
• Pheochromocytoma: Adrenal tumor causing severe hypertension.
• Scoliosis: Severe curvature of the spine requiring surgical correction.

Diagnostic Criteria & Guidelines

Diagnosis is clinical, requiring ≥ 2 of the following: 1) ≥6 café-au-lait macules, 2) ≥2 neurofibromas or 1 plexiform neurofibroma, 3) Axillary/inguinal freckling, 4) Optic glioma, 5) ≥2 Lisch nodules, 6) Distinctive osseous lesion, 7) First-degree relative with NF1. Recent updates allow genetic testing (pathogenic NF1 variant) to serve as a criterion.

Differential Diagnosis

• Legius Syndrome (SPRED1 mutation, has spots but no tumors)
• McCune-Albright Syndrome
• Neurofibromatosis Type 2 (NF2 - features bilateral vestibular schwannomas)

Laboratory Tests & Biomarkers

• Genetic Testing: Identification of a pathogenic heterozygous variant in the NF1 gene.

Imaging Modalities & Findings

• Brain MRI:
• Whole-body MRI / PET scan:

• Childhood
  Appearance of café-au-lait spots, freckling, optic gliomas, and bone dysplasias.
• Adolescence/Adulthood
  Rapid growth of cutaneous and plexiform neurofibromas; risk of MPNST.

Second-Line & Adjunctive Therapy

For Optic Pathway Gliomas causing visual decline, Carboplatin/Vincristine chemotherapy is the standard; radiation is avoided to prevent secondary malignancies. MPNST requires aggressive surgical resection with wide margins, often combined with adjuvant radiation and chemotherapy (Doxorubicin/Ifosfamide).

Surgical & Procedural Management

Surgical excision of symptomatic neurofibromas. Orthopedic surgery for severe scoliosis or tibial pseudarthrosis.

Recommended Lifestyle Changes

• Annual ophthalmology exams for children to detect optic gliomas.
• Annual blood pressure monitoring to screen for renal artery stenosis or pheochromocytoma.
• Psychoeducational support for children with learning disabilities.

Patient Counseling & Advice

Counsel that disease severity is highly variable, even within families. Instruct patients to report rapid growth, new persistent pain, or hardening of any existing neurofibroma immediately, as these are signs of malignant transformation (MPNST). Offer genetic counseling for family planning.

Follow-Up & Monitoring Schedule

Multidisciplinary NF clinic annually: full skin check, neurological exam, BP check, and ophthalmologic evaluation.

Preventive Strategies

Cannot be prevented except through preimplantation genetic diagnosis (PGD) in known carrier parents.

Life expectancy is reduced by 10-15 years compared to the general population, primarily due to malignancies (MPNST) and cardiovascular complications.